Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT03786094. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An International, Phase 3, Multicenter, Randomized, Open- Label Trial Comparing Balixafortide in Combination With Eribulin Versus Eribulin Alone in Patients With HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous balixafortide given with eribulin versus eribulin alone in the treatment of HER2 negative, Locally Recurrent or Metastatic Breast Cancer.
Study identification
- NCT ID
- NCT03786094
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 432 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 30, 2019 (Actual)
- Primary completion
- Oct 19, 2021 (Actual)
- Completion
- Oct 19, 2021 (Actual)
- Last update posted
- Nov 1, 2023
2019 – 2021
United States locations
- U.S. sites
- 28
- U.S. states
- 16
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Cancer Associates for Research and Excellence | Fresno | California | 93720 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| UCSF Mount Zion Cancer Center | San Francisco | California | 94115 | — |
| Stanford Cancer Center South Bay | San Jose | California | 95124 | — |
| Norwalk Hospital | Norwalk | Connecticut | 06856 | — |
| Florida Cancer Specialists SOUTH - SCRI - PPDS | Fort Myers | Florida | 33901 | — |
| Orlando Health | Orlando | Florida | 32806 | — |
| Florida Cancer Specialists NORTH - SCRI - PPDS | St. Petersburg | Florida | 33705 | — |
| Florida Cancer Specialists PAN - SCRI - PPDS | Tallahassee | Florida | 32308 | — |
| Tallahassee Memorial HealthCare | Tallahassee | Florida | 32308 | — |
| Florida Cancer Specialists EAST - SCRI - PPDS | West Palm Beach | Florida | 33401 | — |
| University Cancer and Blood Center, LLC | Athens | Georgia | 30607 | — |
| Piedmont Cancer Institute PC | Atlanta | Georgia | 30318 | — |
| Orchard Healthcare Research Inc | Skokie | Illinois | 60077 | — |
| Herbert-Herman Cancer Center, Sparrow Hospital | Lansing | Michigan | 48912 | — |
| Virginia Piper Cancer Institute | Minneapolis | Minnesota | 55407 | — |
| Saint Luke's Cancer Institute 150 Entrance | Kansas City | Missouri | 63376 | — |
| HCA Midwest Health - SCRI - PPDS | Kansas City | Missouri | 64132 | — |
| Mercy Research Oncology | St Louis | Missouri | 63141 | — |
| CHI Health St. Francis | Grand Island | Nebraska | 68803 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| Queens Hospital Cancer Center | New York | New York | 11432 | — |
| OHSU Knight Cancer Institute Hematology Oncology | Portland | Oregon | 97210 | — |
| Magee Women's Hospital | Pittsburgh | Pennsylvania | 15213 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Vanderbilt University Medical Center | Tennessee City | Tennessee | 37204 | — |
| University of Vermont Medical Center | Burlington | Vermont | 05401 | — |
| West Virginia University Hospital | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 60 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03786094, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 1, 2023 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03786094 live on ClinicalTrials.gov.